Health Canada approves Iqirvo as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis

Ipsen

28 April 2025 - Iqirvo (elafibranor) is the first new medicine approved in nearly a decade for the treatment of rare cholestatic liver disease primary biliary cholangitis.

Ipsen Biopharmaceuticals Canada today announced Health Canada has issued a Notice of Compliance with Conditions approving Iqirvo (elafibranor) for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

Read Ipsen press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada , Registration